The world’s largest dialysis company is seeking out kidney disease patients long before they need the most acute form of care as it plans for growth of new drugs that attack the condition’s causes ...
Indication: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The approval was based on data from the DAPA-CKD trial, which compared dapagliflozin ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved a label update for FARXIGA ® (dapagliflozin) and XIGDUO ® XR (dapagliflozin ...
AstraZeneca’s latest DTC spot “We Are Targets” for its chronic kidney disease (CKD) med Farxiga is aimed squarely at the nine in 10 adults who have CKD but are unaware of it. The new spot is a ...
WILMINGTON, Del.-- (BUSINESS WIRE)--AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of FARXIGA (dapagliflozin) to ...
New diabetes drugs also shown to slow kidney decline Dialysis company FMC sees impact on its grow outlook Fresenius Medical in push into earlier stages of kidney disease Separate Reuters factbox gives ...
FRANKFURT (Reuters) -The world’s largest dialysis company is seeking out kidney disease patients long before they need the most acute form of care as it plans for growth of new drugs that attack the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback